Unit
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
A phase II trial of 5-fluorouracil and 1-leucovorin in patients with metastatic colorectal cancer
Erlichman C, Fine S, Kerr I, Hoffmann W, Gorg C, Schmoll H, Preusser P, Thürlimann B, Gustavsson B. A phase II trial of 5-fluorouracil and 1-leucovorin in patients with metastatic colorectal cancer. American journal of clinical oncology 1996; 19:26-31.
Feb 1, 1996A phase II trial of 5-fluorouracil and 1-leucovorin in patients with metastatic colorectal cancer
Feb 1, 1996American journal of clinical oncology 1996; 19:26-31
Erlichman C, Fine S, Kerr I, Hoffmann W, Gorg C, Schmoll H J, Preusser P, Thürlimann Beat, Gustavsson B
Verdrängtes tönen lassen:
Renz M. Verdrängtes tönen lassen:. INTRA. Psychologie und Gesellschaft 1996; 26:18-25.
Jan 1, 1996Verdrängtes tönen lassen:
Jan 1, 1996INTRA. Psychologie und Gesellschaft 1996; 26:18-25
Renz Monika
Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy
Pecherstorfer M, Huss H, van Eijkeren M, Steinhauer E, Tubiana-Hulin M, Thürlimann B, Clemens M, Degardin M, Manegold C, Body J, Herrmann Z, Thiébaud D. Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996; 14:268-76.
Jan 1, 1996Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy
Jan 1, 1996Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996; 14:268-76
Pecherstorfer M, Huss H J, van Eijkeren M, Steinhauer E U, Tubiana-Hulin M, Thürlimann Beat, Clemens M R, Degardin M, Manegold C, Body J J, Herrmann Z, Thiébaud D
[Prognostic significance of p53 autoantibodies in serum of patients with breast carcinoma]
Huober J, Sprenger H, Costa S, Zentgraf H, Schmid H, Kaufmann M, Bastert G. [Prognostic significance of p53 autoantibodies in serum of patients with breast carcinoma]. Zentralblatt für Gynäkologie 1996; 118:560-4.
Jan 1, 1996[Prognostic significance of p53 autoantibodies in serum of patients with breast carcinoma]
Jan 1, 1996Zentralblatt für Gynäkologie 1996; 118:560-4
Huober Jens, Sprenger H, Costa S D, Zentgraf H, Schmid H, Kaufmann M, Bastert G
[Metastasis to the sternum or parasternal recurrence of breast carcinoma? Value of sonography]
Mende U, Huober J, Schmid H, Winterbauer T, Bastert G, Wannenmacher M. [Metastasis to the sternum or parasternal recurrence of breast carcinoma? Value of sonography]. Der Radiologe 1996; 36:22-30.
Jan 1, 1996[Metastasis to the sternum or parasternal recurrence of breast carcinoma? Value of sonography]
Jan 1, 1996Der Radiologe 1996; 36:22-30
Mende U, Huober Jens, Schmid H, Winterbauer T, Bastert G, Wannenmacher M
Oral antitumor activity in murine L1210 leukemia and pharmacological properties of liposome formulations of N4-alkyl derivatives of 1-beta-D-arabinofuranosylcytosine (ara-C)
Schwendener R, Horber D, Odermatt B, Schott H. Oral antitumor activity in murine L1210 leukemia and pharmacological properties of liposome formulations of N4-alkyl derivatives of 1-beta-D-arabinofuranosylcytosine (ara-C). J Cancer Res Clin Oncol 1996; 122:102-108.
Jan 1, 1996Oral antitumor activity in murine L1210 leukemia and pharmacological properties of liposome formulations of N4-alkyl derivatives of 1-beta-D-arabinofuranosylcytosine (ara-C)
Jan 1, 1996J Cancer Res Clin Oncol 1996; 122:102-108
Schwendener R., Horber Daniel, Odermatt B., Schott H.
Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance
Drach J, Ludwig H, Geissler K, Fiegl M, Jäger U, Haas O, Thalhammer R, Rothermundt C, Schuster J, Angerler J, Huber H. Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance. Blood 1995; 86:3915-21.
Nov 15, 1995Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance
Nov 15, 1995Blood 1995; 86:3915-21
Drach J, Ludwig H, Geissler K, Fiegl M, Jäger U, Haas O A, Thalhammer R, Rothermundt Christian, Schuster J, Angerler J, Huber H
Cell cycle dependent cytotoxicity and induction of apoptosis by N4-hexadecyl-1-beta-D-arabinofuranosylcytosine, a new lipophilic derivative of 1-beta-D-arabinofuranosylcytosine
Horber D, von Ballmoos P, Schott H, Schwendener R. Cell cycle dependent cytotoxicity and induction of apoptosis by N4-hexadecyl-1-beta-D-arabinofuranosylcytosine, a new lipophilic derivative of 1-beta-D-arabinofuranosylcytosine. Br J Cancer 1995; 72:1067-1073.
Nov 1, 1995Cell cycle dependent cytotoxicity and induction of apoptosis by N4-hexadecyl-1-beta-D-arabinofuranosylcytosine, a new lipophilic derivative of 1-beta-D-arabinofuranosylcytosine
Nov 1, 1995Br J Cancer 1995; 72:1067-1073
Horber Daniel, von Ballmoos P., Schott H., Schwendener R.
Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization
Drach J, Jäger U, Gsur A, Rothermundt C, Fiegl M, Rosenthal F, Angerler J, Nowotny H, Schuster J, Heinz R. Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization. Cancer research 1995; 55:3854-9.
Sep 1, 1995Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization
Sep 1, 1995Cancer research 1995; 55:3854-9
Drach J, Jäger U, Gsur A, Rothermundt Christian, Fiegl M, Rosenthal F, Angerler J, Nowotny H, Schuster J, Heinz R
Influence of serum on zinc, toxic shock syndrome toxin-1, and lipopolysaccharide-induced production of IFN-gamma and IL-1 beta by human mononuclear cells
Driessen C, Hirv K, Wellinghausen N, Kirchner H, Rink L. Influence of serum on zinc, toxic shock syndrome toxin-1, and lipopolysaccharide-induced production of IFN-gamma and IL-1 beta by human mononuclear cells. Journal of leukocyte biology 1995; 57:904-8.
Jun 1, 1995Influence of serum on zinc, toxic shock syndrome toxin-1, and lipopolysaccharide-induced production of IFN-gamma and IL-1 beta by human mononuclear cells
Jun 1, 1995Journal of leukocyte biology 1995; 57:904-8
Driessen Christoph, Hirv K, Wellinghausen N, Kirchner H, Rink L
Central versus peripheral site of action of the tachykinin NK1-antagonist RP 67580 in inhibiting chemonociception.
Holzer-Petsche U, Rordorf T. Central versus peripheral site of action of the tachykinin NK1-antagonist RP 67580 in inhibiting chemonociception. Br J Pharmacol 1995; 115:486-90.
Jun 1, 1995Central versus peripheral site of action of the tachykinin NK1-antagonist RP 67580 in inhibiting chemonociception.
Jun 1, 1995Br J Pharmacol 1995; 115:486-90
Holzer-Petsche U, Rordorf Tamara
Pharmacokinetic properties and interactions with blood components of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine (NHAC) incorporated into liposomes
Horber D, Ottiger C, Schott H, Schwendener R. Pharmacokinetic properties and interactions with blood components of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine (NHAC) incorporated into liposomes. J Pharm Pharmacol 1995; 47:282-288.
Apr 12, 1995Pharmacokinetic properties and interactions with blood components of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine (NHAC) incorporated into liposomes
Apr 12, 1995J Pharm Pharmacol 1995; 47:282-288
Horber Daniel, Ottiger C., Schott H., Schwendener R.
Regulation of phosphatidylinositol 3'-kinase by tyrosyl phosphoproteins. Full activation requires occupancy of both SH2 domains in the 85-kDa regulatory subunit.
Rordorf T, Van Horn D, Chen D, White M, Backer J. Regulation of phosphatidylinositol 3'-kinase by tyrosyl phosphoproteins. Full activation requires occupancy of both SH2 domains in the 85-kDa regulatory subunit. J Biol Chem 1995; 270:3662-6.
Feb 24, 1995Regulation of phosphatidylinositol 3'-kinase by tyrosyl phosphoproteins. Full activation requires occupancy of both SH2 domains in the 85-kDa regulatory subunit.
Feb 24, 1995J Biol Chem 1995; 270:3662-6
Rordorf Tamara, Van Horn D J, Chen D C, White M F, Backer J M
Divergent effects of zinc on different bacterial pathogenic agents
Driessen C, Hirv K, Kirchner H, Rink L. Divergent effects of zinc on different bacterial pathogenic agents. The Journal of infectious diseases 1995; 171:486-9.
Feb 1, 1995Divergent effects of zinc on different bacterial pathogenic agents
Feb 1, 1995The Journal of infectious diseases 1995; 171:486-9
Driessen Christoph, Hirv K, Kirchner H, Rink L
Zinc regulates cytokine induction by superantigens and lipopolysaccharide
Driessen C, Hirv K, Kirchner H, Rink L. Zinc regulates cytokine induction by superantigens and lipopolysaccharide. Immunology 1995; 84:272-7.
Feb 1, 1995Zinc regulates cytokine induction by superantigens and lipopolysaccharide
Feb 1, 1995Immunology 1995; 84:272-7
Driessen Christoph, Hirv K, Kirchner H, Rink L
Mouse interleukin-12 (IL-12) p40 homodimer: a potent IL-12 antagonist
Gillessen Sommer S, Stern A, Presky D, Gubler U, Familletti P, Stremlo D, Podlaski F, Ling P, Carvajal D, Gately M. Mouse interleukin-12 (IL-12) p40 homodimer: a potent IL-12 antagonist. European journal of immunology 1995; 25:200-6.
Jan 1, 1995Mouse interleukin-12 (IL-12) p40 homodimer: a potent IL-12 antagonist
Jan 1, 1995European journal of immunology 1995; 25:200-6
Gillessen Sommer Silke, Stern A S, Presky D H, Gubler U, Familletti P C, Stremlo D L, Podlaski F J, Ling P, Carvajal D, Gately M K
Dexverapamil to overcome epirubicin resistance in advanced breast cancer
Thürlimann B, Hartlapp J, Gastl G, Schumacher K, Schernhammer E, Schüller J, Mross K, Greiner J, Kröger N, Kupper H. Dexverapamil to overcome epirubicin resistance in advanced breast cancer. Journal of cancer research and clinical oncology 1995; 121 Suppl 3:R3-6.
Jan 1, 1995Dexverapamil to overcome epirubicin resistance in advanced breast cancer
Jan 1, 1995Journal of cancer research and clinical oncology 1995; 121 Suppl 3:R3-6
Thürlimann Beat, Hartlapp J, Gastl G, Schumacher K, Schernhammer E, Schüller J, Mross K, Greiner J, Kröger N, Kupper H
Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. Swiss Group for Clinical Cancer Research (SAKK)
Joss R, Stahel R, Martinelli G, Cerny T, Thürlimann B, Leyvraz S, Bacchi M, Hürny C, Alberto P, Ludwig C. Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. Swiss Group for Clinical Cancer Research (SAKK). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995; 6:41-8.
Jan 1, 1995Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. Swiss Group for Clinical Cancer Research (SAKK)
Jan 1, 1995Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995; 6:41-8
Joss R A, Stahel R, Martinelli G, Cerny T, Thürlimann Beat, Leyvraz S, Bacchi M, Hürny C, Alberto P, Ludwig C
Cellular pharmacology of a liposomal preparation of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine, a lipophilic derivative of 1-beta-D-arabinofuranosylcytosine
Horber D, Schott H, Schwendener R. Cellular pharmacology of a liposomal preparation of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine, a lipophilic derivative of 1-beta-D-arabinofuranosylcytosine. Br J Cancer 1995; 71:957-962.
Jan 1, 1995Cellular pharmacology of a liposomal preparation of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine, a lipophilic derivative of 1-beta-D-arabinofuranosylcytosine
Jan 1, 1995Br J Cancer 1995; 71:957-962
Horber Daniel, Schott H., Schwendener R.
Cellular pharmacology of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine (NHAC) in the human leukemic cell lines K-562 and U-937
Horber D, Schott H, Schwendener R. Cellular pharmacology of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine (NHAC) in the human leukemic cell lines K-562 and U-937. Cancer Chemother Pharmacol 1995; 36:483-492.
Jan 1, 1995Cellular pharmacology of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine (NHAC) in the human leukemic cell lines K-562 and U-937
Jan 1, 1995Cancer Chemother Pharmacol 1995; 36:483-492
Horber Daniel, Schott H., Schwendener R.